Drug details

Otrexup PFS (methotrexate injection)

type of

Otrexup PFS (methotrexate) is a folate analog metabolic inhibitor indicated for the management of patients with severe, active rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis (pJIA), who are intolerant of or had an inadequate response to first-line therapy; and for symptomatic control of severe, recalcitrant, disabling psoriasis in adults who are not adequately responsive to other forms of therapy. The brand name Otrexup PFS had been discontinued. Generic versions of methotrexate are available.

The drug is often used to treat Arthritis , Psoriasis .

This drug may have the following side effects:

• nausea,
• headache,
• dizziness,
• vomiting,
• diarrhea,
• runny or stuffy nose,
• mouth sores,
• abdominal pain,
• indigestion,
• rash,
• low platelet count (thrombocytopenia),
• hair loss,
• photosensitivity,
• bronchitis,
• liver function test abnormalities,
• low white blood cell count (leucopenia),
• low red and white blood cell counts (pancytopenia),
• "burning of skin lesions."

The following drugs are related to Otrexup PFS, either as a replacement or used together:

• Emerphed (ephedrine sulfate injection)
• Mobic (meloxicam)
• Otrexup (methotrexate injection)
• RediTrex (methotrexate injection)